Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers
Year: 2019
Type: review
Source: The Lancet Oncology
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Keywords: triple-negative breast cancer, HER2-positive breast cancer, early breast cancer, neoadjuvant chemotherapy, treatment sequencing, adjuvant therapy, KATHERINE trial, trastuzumab emtansine, capecitabine, residual invasive disease, estrogen receptor-negative breast cancer, disease-free survival
Open Access status: closed
OpenAlex ID: W2954662492
